A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs LAG 525 (Primary) ; PDR 001 (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 15 Nov 2017 Planned number of patients changed from 416 to 515.
- 26 Jun 2017 Planned End Date changed from 12 Oct 2018 to 28 Apr 2019.
- 26 Jun 2017 Planned primary completion date changed from 12 Oct 2018 to 28 Apr 2019.